Bortezomib

Analysis showed ~87% of patients treated with TECVAYLI ® ▼ plus daratumumab as early as second line were estimated to have comparable mortality risk to the general population 1 A separate analysis shows the survival benefit was driven by a 90% reduction in the risk of multiple myeloma progression versus standard of care, with no significant difference in rates of non-relapse mortality 2 BEERSE, Belgium, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson, a worldwide leader in multiple myeloma, today announced new data from the Phase 3 MajesTEC-3 study showing sustained disease control and survival with TECVAYLI ® (teclistamab) plus daratumumab in patients with relapsed or refractory multiple myeloma (RRMM) who had received 1-3 prior lines of therapy. In an analysis to be presented in Abstract #OA-58, statistical modelling estimated that more than 85% of patients treated with teclistamab plus daratumumab may experience a mortality risk and projected life expectancy similar to an age-matched general population. 1 The analysis used a relative survival mixture cure model (MCM) and actual progression-free survival (PFS) and overall survival (OS) data from MajesTEC-3. 1 Modelling further predicted that median OS with teclistamab plus daratumumab would be nearly four-fold longer than with the standard-of-care comparator in the study, daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd). 1 These data help to illustrate to what extent treatment with teclistamab plus daratumumab as early as second line may reshape survival expectations in multiple myeloma. Post-hoc analysis provides insight into the survival benefit In the MajesTEC-3 study, teclistamab plus daratumumab significantly improved OS versus SOC, with an estimated 83% of patients alive at three years. 2 A post hoc analysis (Abstract #OA-49) showed that teclistamab plus daratumumab reduced the risk of cumulative incidence of disease progression by 90% versus SOC, with no significant difference in non-relapse mortality over time between the treatment arms. 2 These data will be presented in two oral sessions at the International Myeloma Society (IMS) Annual Meeting. Complementary mechanisms of action underpin this immunotherapy doublet Teclistamab and daratumumab work in a complementary manner, with daratumumab modulating the immune system to enhance T-cell fitness and activation, thereby amplifying teclistamab-mediated killing of myeloma cells. 3 Expert and company perspectives emphasise the potential for durable, long-term disease control “These findings underscore how consequential treatment choice at first relapse can be in shaping a patient’s long-term trajectory,” said Dr. Luciano J. Costa, Professor of Multiple Myeloma and Director of the Multiple Myeloma Research and Treatment Program at the University of Alabama at Birmingham.* “The sustained disease control observed with teclistamab plus daratumumab is changing expectations for what treatment can achieve in relapsed or refractory multiple myeloma, moving beyond just delaying the next relapse toward the possibility of durable long-term disease control.” “Seeing projected life expectancy for patients with relapsed or refractory multiple myeloma potentially approach that of the general population is an exciting and hopeful signal of what may be possible with teclistamab plus daratumumab,” said Ester in ‘t Groen, EMEA Therapeutic Area Head, Haematology, Johnson & Johnson. “Alongside the growing body of positive clinical evidence, these analyses reinforce our convictions that this combination offers a new standard of care – one where outcomes once considered difficult to imagine could become increasingly achievable for patients.” “The continued analyses of the MajesTEC-3 trial challenge long-held expectations of what may be possible in multiple myeloma,” said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson. “Our ambition is to build on this progress by fundamentally changing the long-term trajectory of multiple myeloma and, ultimately, creating a future in which this disease is no longer defined as incurable.” Model-based analysis projects potential long-term survival outcomes The MajesTEC-3 study evaluated teclistamab plus daratumumab versus investigator’s choice of DPd/DVd in patients with RRMM who had received 1-3 prior lines of therapy. In this analysis, a relative survival MCM was applied to patients treated with teclistamab plus daratumumab (n=291) and DPd/DVd (n=296) to assess whether long-term disease control could translate into outcomes approaching those of the general population. 1 Best-fit models estimated cure fractions of 86.6% (95% confidence interval [CI], 81–91) for OS with the combination, compared with 0% (95% CI, 0–53) with DPd/DVd, with substantially greater uncertainty in the DPd/DVd estimates. 1 Model projected remaining life expectancy was 18.5 years with the teclistamab plus daratumumab combination, nearly four times the 4.9 years projected with DPd/DVd and approaching 21.1 years for the matched general population. 1 Reduced disease progression drives survival benefit A separate post hoc analysis provided further insight into the survival benefit observed in MajesTEC-3. At 36 months, the cumulative incidence of disease progression was 8.7% with teclistamab plus daratumumab versus 62.1% with DPd/DVd, representing a 90% reduction in the risk of disease progression (sub-distribution hazard ratio [sHR]=0.10; 95% CI, 0.07–0.16; p <0.0001). 2 The 36-month OS rate was 83.3% versus 65.0%, respectively (HR=0.46; 95% CI, 0.32–0.65; p <0.0001). 2 There was no significant difference in non-relapse mortality between treatment groups, with 36-month rates of 10.2% with teclistamab plus daratumumab and 9.0% with DPd/DVd (sHR=1.16; 95% CI, 0.69–1.98; p =0.5668). 2 No statistically significant difference in overall survival was observed between the treatment groups during the first 10 months (HR=1.08; 95% CI, 0.64–1.81). 2 After 10 months, overall survival favoured teclistamab plus daratumumab, with a 78% reduction in the risk of death compared with DPd/DVd (HR=0.22; 95% CI, 0.13–0.38). 2 A prespecified restricted mean survival time analysis also supported a significant overall survival benefit, with a difference of 2.15 months during the period analysed ( p =0.0088). 2 Together, these analyses provide complementary evidence supporting the long-term benefit observed with teclistamab plus daratumumab. While the MCM analysis suggests the potential for highly durable disease control to extend OS for patients with multiple myeloma relative to the general population, the competing risk analysis helps explain these outcomes by demonstrating a profound reduction in disease progression without a significant increase in non-relapse mortality. 1,2 MajesTEC-3 is ongoing, and continued follow-up will assess whether observed outcomes confirm these model-based predictions. About the MajesTEC-3 Study MajesTEC-3 ( NCT05083169 ) is an ongoing, Phase 3 randomised study evaluating the safety and efficacy of teclistamab plus daratumumab subcutaneous (SC) (n=291) versus investigator’s choice of daratumumab SC and dexamethasone with either pomalidomide or bortezomib (n=296) (DPd/DVd) in patients with relapsed/refractory multiple myeloma (RRMM) who have received one to three prior lines of therapy. 3, 4 The primary endpoint is progression-free survival (PFS) and secondary endpoints include complete response or better (≥CR), overall response rate (ORR), minimal residual disease (MRD) negativity (10⁻⁵ by next-generation sequencing), overall survival (OS), time to worsening of symptoms (MySIm-Q), and safety. 4 The MajesTEC-3 study is a part of the MajesTEC clinical programme, which includes exploring the potential of teclistamab as a combination regimen. 4 About Teclistamab Teclistamab received European Commission (EC) approval in August 2022 for the treatment of patients with RRMM who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. 5 In August 2026, the EC approved teclistamab in combination with daratumumab for the treatment of patients with RRMM who have received at least one prior therapy, providing a treatment option as early as second line. 6 Teclistamab is an off-the-shelf (or ready-to-use) bispecific antibody. 7 , 8 Teclistamab, a subcutaneous injection, redirects T-cells through two cellular targets (BCMA and CD3) to activate the body’s immune system to fight cancer. 7 Teclistamab is currently being evaluated in several combination studies. 9 ,1 0 ,1 1 ,1 2 To date, more than 30,700 patients have been treated worldwide with teclistamab. 1 3 For a full list of adverse events and information on dosage and administration, contraindications and other precautions when using teclistamab, please refer to the Summary of Product Characteristics at: . ▼ In line with EMA regulations for new medicines and those given conditional approval, teclistamab is subject to additional monitoring. 7 About Daratumumab and Daratumumab SC Johnson & Johnson is committed to exploring the potential of daratumumab for patients with multiple myeloma across the spectrum of the disease. In August 2012 , Janssen Biotech, Inc., a Johnson & Johnson company, and Genmab A/S entered a worldwide agreement, which granted Johnson & Johnson an exclusive licence to develop, manufacture and commercialise daratumumab. Since launch, daratumumab has become a foundational therapy in the treatment of multiple myeloma, having been used in the treatment of more than 830,000 patients worldwide. 1 4 Daratumumab was the first CD38-directed antibody approved to be given subcutaneously to treat patients with multiple myeloma. 1 5,16 Daratumumab SC was also the first oncology injectable approved for administration by patients living with multiple myeloma or their caregivers from the fifth dose, if determined to be appropriate by their healthcare professional and following proper training. 1 5 , 1 7 Daratumumab SC is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE ® drug delivery technology. 1 5 CD38 is a surface protein that is present in high numbers on multiple myeloma cells, regardless of the stage of disease. 1 5 , 17 Daratumumab binds to CD38 and inhibits tumour cell growth causing myeloma cell death. 18 Daratumumab may also have an effect on normal cells. 1 5 Data across ten Phase 3 clinical trials, in both the frontline and relapsed settings across all newly diagnosed multiple myeloma patients, have shown that daratumumab-based regimens resulted in significant improvement in progression-free survival and/or overall survival. 19,20,21,22,23,24,25,26,27,28 For further information on daratumumab, please see the Summary of Product Characteristics at: . About Multiple Myeloma Multiple myeloma is a complex blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow. 29,30 In multiple myeloma, these malignant plasma cells continue to proliferate, accumulating in the body and crowding out normal blood cells, as well as often causing bone destruction and other serious complications. 3 1 ,3 2 In the European Union, it is estimated that more than 35,000 people were diagnosed with multiple myeloma in 2024, and more than 21,900 patients died. 3 3 Patients living with multiple myeloma experience relapses which become more frequent with each line of therapy, while remissions become progressively shorter. 3 4,35,36 Whilst some patients with multiple myeloma initially have no symptoms, others can have common signs and symptoms of the disease, which can include bone fracture or pain, low red blood cell counts, fatigue, high calcium levels, infections, or kidney damage. 3 7 About Johnson & Johnson’s Multiple Myeloma Portfolio Johnson & Johnson is a global leader in multiple myeloma therapies, with a broad and differentiated portfolio designed to address the complexity and heterogeneity of the disease. Our portfolio spans multiple mechanisms of action, targets and treatment modalities, including CD38-directed therapies, BCMA- and GPRC5D-targeting bispecific antibodies, and cellular therapies. Over the past decade, Johnson & Johnson therapies have helped extend survival for patients with multiple myeloma. With the right medicines, used as early as possible, combined and sequenced for the best results, Johnson & Johnson is expanding treatment options to match the right therapy to the right patient at the right stage of disease and drive deeper and more durable responses. Through ongoing research and a robust clinical program, Johnson & Johnson is committed to transforming multiple myeloma into a more manageable condition that is no longer treated to progression but has the potential to, ultimately, be cured. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at . Follow us at . Cautions Concerning Forward-Looking Statements This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of teclistamab and daratumumab. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at , , or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Key Search Terms MajesTEC-3 Phase 3 clinical trial TECVAYLI Teclistamab DARZALEX Daratumumab Teclistamab and daratumumab combination TECVAYLI and DARZALEX combination Relapsed and or refractory multiple myeloma (RRMM) Early relapse multiple myeloma Second line multiple myeloma treatment First relapse therapy for multiple myeloma Treatment resistance in multiple myeloma Progression-free survival (PFS) in multiple myeloma Overall survival (OS) in multiple myeloma Multiple myeloma Bispecific antibody therapy CD38-targeted therapy BCMA-targeted bispecific therapy Combination immunotherapy EMEA haematology pipeline Multiple myeloma innovation Multiple myeloma treatment *Dr. Luciano J. Costa, Professor of Multiple Myeloma and Director of the Multiple Myeloma Research and Treatment Program at the University of Alabama at Birmingham, has provided consulting, advisory, and speaking services to Johnson & Johnson; he has not been paid for any media work. CP-604037 September 2026 END References: 1 van den Donk Niels., et al. Projecting Functional Cure in Patients with Relapsed/Refractory Multiple Myeloma(RRMM) in the MajesTEC-3 Study ofTeclistamab-Daratumumab (Tec-Dara) Usinga Mixture Cure Model . Presented at: 2026 International Myeloma Society Meeting; 23 September; Glasgow. 2 Costa L., et al. Overall Survival, Progression and Non-Relapse Mortality With Teclistamab Plus Daratumumab ​(Tec-Dara) vs Dara-Based Triplets in Relapsed/Refractory Multiple Myeloma (RRMM): MajesTEC-3 Post Hoc Analysis . Presented at: 2026 International Myeloma Society Meeting; 23 September; Glasgow. 3 Costa L, et al. Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. The New England Journal of Medicine. 2025; Full article and supplementary material. Available at: . Last accessed: September 2026. 4 ClinicalTrials.gov. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3). Available at: . Last accessed: September 2026. 5 Johnson & Johnson.com. Janssen Marks First Approval Worldwide for TECVAYLI®▼(teclistamab) with EC Authorisation of First-in-Class Bispecific Antibody for the Treatment of Patients with Multiple Myeloma. Available at: . Last accessed: September 2026. 6 Johnson & Johnson.com. European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care. Available at: . Last accessed: September 2026. 7 European Medicines Agency. TECVAYLI Summary of Product Characteristics. Available at: . Last accessed: September 2026. 8 Moreau P, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine. 2022;287(6):494-505. 9 ClinicalTrials.gov. A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (MajesTEC-2). Available at: . Last accessed: September 2026. 1 0 ClinicalTrials.gov. A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma. Available at: . Last accessed: September 2026. 1 1 ClinicalTrials.gov. A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma. Available at: . Last accessed: September 2026. 1 2 ClinicalTrials.gov. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3). Available at: . Last accessed: September 2026. 1 3 J&J Data on File. Number of Patients Treated with TECVAYLI Worldwide as of June 2026. 1 4 J&J Data on File. Number of Patients Treated with DARZALEX ® Worldwide as of August 2026. 1 5 European Medicines Agency. DARZALEX Summary of Product Characteristics. Available at: . Last accessed: September 2026. 1 6 Janssen EMEA. European Commission Grants Marketing Authorisation for DARZALEX ® (Daratumumab) Subcutaneous Formulation for All Currently Approved Daratumumab Intravenous Formulation Indications. Available at: . Last accessed: September 2026. 1 7 J&J Data on File. DARZALEX® is the first oncology injectable approved for self-administration by patients or caregivers as of March 2026. 18 Fedele G, et al. CD38 ligation in peripheral blood mononuclear cells of myeloma patients induces release of protumorigenic IL-6 and impaired secretion of IFNy cytokines and proliferation. Mediators Inflamm. 2013;564687. 19 Moreau P, et al. Bortezomib, Thalidomide, and Dexamethasone With or Without Daratumumab Before and After Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (CASSIOPEIA): A Randomised, Open-label, Phase 3 Study. Lancet. 2019;394(10192):29-38. 2 0 Facon T, et al. MAIA Trial Investigators. Daratumumab Plus Lenalidomide and Dexamethasone for Untreated Myeloma. New England Journal of Medicine. 2019;380(22):2104-2115. 2 1 Mateos MV, et al. Overall Survival with Daratumumab, Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma (ALCYONE): A Randomised, Open-label, Phase 3 Trial. The Lancet. 2020;395(10218):132-141. 2 2 Dimopoulos MA, et al. APOLLO Trial Investigators. Daratumumab Plus Pomalidomide and Dexamethasone Versus Pomalidomide and Dexamethasone Alone in Previously Treated Multiple Myeloma (APOLLO): An Open-label, Randomised, Phase 3 Trial. Lancet Oncol. 2021;22(6):801-812. 2 3 Palladini G, et al. Daratumumab Plus CyBorD for Patients with Newly Diagnosed AL Amyloidosis: Safety Run-in Results of ANDROMEDA. Blood. 2020;2;136(1):71-80. 2 4 Chari A, et al. Daratumumab Plus Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma. Blood. 2017;130(8):974-981. 2 5 Bahlis NJ, et al. Daratumumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended Follow-up of POLLUX, A Randomized, Open-label, Phase 3 study. Leukemia. 2020;34(7):1875-1884. 2 6 Mateos MV, et al. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Previously Treated Multiple Myeloma: Three-Year Follow-up of CASTOR. Clin Lymphoma Myeloma Leuk. 2020;20(8):509-518. 2 7 Usmani S Z, et al. Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients with Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study. Oral Presentation. 21 st International Myeloma Society (IMS) Annual Meeting. September 25 – 28, 2024. 28 Sonneveld P, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine. 2024; 390(4):301-313. 29 Abdi J, et al. Drug Resistance in Multiple Myeloma: Latest Findings on Molecular Mechanisms. Oncotarget. 2013;4(12):2186-2207. 3 0 Myeloma UK. What is myeloma? Available at: . Last accessed: September 2026. 3 1 Lungu O, et al. Mechanistic insights into bone destruction in multiple myeloma: cellular and molecular perspectives. Journal of Bone Oncology. 2025;51:100668. 3 2 Mayo Clinic. Multiple Myeloma. Available at: 20353378 . Last accessed: September 2026. 3 3 ECIS - European Cancer Information System. Estimates of Cancer Incidence and Mortality in 2024, by Country. Multiple Myeloma. Available at: . Last accessed: September 2026. 3 4 Bhatt P, et al. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. Curr Oncol. 2023;30(2):2322-2347. 3 5 Hernández-Rivas JÁ, et al. The Changing Landscape of Relapsed and/or Refractory Multiple Myeloma (MM): Fundamentals and Controversies. Biomark Res. 2022;10(1):1-23. 3 6 Gavriatopoulou M, et al. Metabolic Disorders in Multiple Myeloma. Int J Mol Sci. 2021;22(21):11430. 3 7 American Cancer Society. Multiple Myeloma: Early Detection, Diagnosis and Staging. Available at: . Last accessed: September 2026. CONTACT: Media contact: Jenni Mildon jmildon@its.jnj.com +44 7920 418 552 Investorcontact: JessMargevich investor-relations@its.jnj.com

Newly allowed claims provide LP‑284 patent protection into 2042 for the treatment of mantle cell lymphoma and double-hit lymphoma, two blood cancers with high-unmet-needs The U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, "Method for Treating Blood Cancers," with claims directed to the use of LP‑284 (hydroxyureamethyl acylfulvene) to treat mantle cell lymphoma (MCL) and double‑hit lymphoma (DHL) Allowed claims include methods of treatment as a monotherapy and in combination with a second anti‑cancer agent — including DNA damage agents, glucocorticoids, immunomodulatory drugs (IMiDs), BCL2 inhibitors, BTK inhibitors, spironolactone, PARP inhibitors, and proteasome inhibitors Once issued, the patent is expected to extend Lantern's LP‑284 patent protection into 2042, complementing the existing composition‑of‑matter estate that provides protection into 2039 across major markets LP‑284 holds three FDA Orphan Drug Designations — in MCL, high‑grade B‑cell lymphoma (HGBL) with MYC and BCL2 rearrangements, and soft tissue sarcomas — and is being evaluated in an ongoing Phase 1 clinical trial (NCT06132503) DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an AI‑driven precision oncology company transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, titled "Method for Treating Blood Cancers," with claims directed to the use of the company's drug candidate LP‑284 to treat patients with mantle cell lymphoma (MCL), double‑hit lymphoma (DHL), and other blood cancers. The allowed claims cover methods of treating a subject diagnosed with blood cancer by administering an effective amount of LP‑284, when the cancer is mantle cell lymphoma or double‑hit lymphoma. Additional allowed claims cover the co‑administration of LP‑284 with a second anti‑cancer agent selected from: DNA damaging agents, glucocorticoids, immunomodulatory drugs (IMiDs), BCL2 inhibitors, Bruton's tyrosine kinase (BTK) inhibitors, spironolactone, PARP inhibitors, and proteasome inhibitors. Additional claims also cover routes of administration including intravenous and intraperitoneal delivery. A Notice of Allowance is issued after the USPTO determines that prosecution on the merits of a patent application has concluded, and the patent grants upon payment of the required issuance fee. "This Notice of Allowance marks an important step in building a durable, layered intellectual-property portfolio around LP‑284,” said Panna Sharma, President and Chief Executive Officer of Lantern Pharma. “The anticipated patent claims cover the use of LP‑284 as a monotherapy and in combination with other therapeutic agent classes for mantle cell lymphoma and double-hit lymphoma, two aggressive B-cell lymphomas with significant unmet needs globally. Together with our composition-of-matter patent estate, this patent is expected to provide LP‑284 protection into 2042 and strengthen the program’s long-term commercial potential. Advancing LP‑284 from AI-generated insights through our RADR® platform to a first-in-human clinical trial in less than three years demonstrates the potential of our precision approach to efficient, data-driven drug development for novel therapies.” Strengthening a Global LP‑284 Patent Estate The newly allowed method‑of‑treatment patent builds on Lantern's existing LP‑284 composition‑of‑matter estate, which provides protection into 2039 across major medicine markets, including the United States, European Union, Japan, China, India, Mexico, Korea, and Australia. Lantern received its first U.S. composition‑of‑matter Notice of Allowance for LP‑284 in April 2023, followed by a Certificate of Patent from the Japan Patent Office in June 2024 and a European Patent Office allowance in July 2025. Once issued, the "Method for Treating Blood Cancers" patent is expected to extend Lantern's LP‑284 protection into 2042, adding a distinct layer of method‑of‑use protection on top of the underlying composition‑of‑matter rights. Lantern intends to continue prosecuting additional patent applications directed to further indications, combination regimens, and formulations of LP‑284 to further strengthen its intellectual property portfolio. LP‑284 — An AI‑Optimized, Next‑Generation Acylfulvene for Aggressive B‑Cell Cancers LP‑284 is an investigational, next‑generation acylfulvene and the stereoisomer (enantiomer) of Lantern's drug candidate LP‑184. It was optimized using Lantern's proprietary RADR® artificial intelligence platform, which identified its synthetically lethal mechanism targeting cancer cells with DNA damage repair (DDR) deficiencies. Unlike LP‑184, whose activity depends on the enzyme PTGR1, LP‑284's cytotoxic activity is independent of PTGR1 expression, making it well suited to hematologic malignancies. LP‑284 induces DNA lesions that are primarily repaired by the transcription‑coupled nucleotide excision repair (TC‑NER) pathway, and its activity is retained in tumors deficient in ATM — a gene inactivated in an estimated 40%–50% of MCL patients — as well as regardless of TP53 mutation status or lymphoma surface antigen expression. In preclinical studies, LP‑284 has demonstrated nanomolar potency across a panel of B‑cell non‑Hodgkin's lymphoma models, with the highest potency observed in MCL cell lines, including lines resistant to standard‑of‑care agents. In data presented at the 2022 Society of Hematologic Oncology (SOHO) Annual Meeting, LP‑284 showed its lowest IC50 of 88 nM in the bortezomib‑resistant MINO MCL cell line and 193 nM in the ibrutinib/venetoclax‑resistant MAVER‑1 line, demonstrating activity even in models resistant to ibrutinib, bortezomib, venetoclax, and zanubrutinib. LP‑284 has also shown preclinical synergy with rituximab in high‑grade B‑cell lymphoma models, and combination with spironolactone enhanced sensitivity to LP‑284 by 2.4‑fold in a multiple myeloma cell line. LP‑284 holds three FDA Orphan Drug Designations: for mantle cell lymphoma (granted January 2023), for high‑grade B‑cell lymphoma with MYC and BCL2 rearrangements (granted November 2023), and for soft tissue sarcomas (granted January 2026). These represent three of the six total Orphan Drug Designations granted across Lantern's clinical pipeline. Clinical Program LP‑284 is currently being evaluated in an ongoing Phase 1a dose‑escalation clinical trial (NCT06132503) in patients with relapsed or refractory B‑cell non‑Hodgkin's lymphomas and solid tumors. In 2025, Lantern reported that a heavily pretreated 41‑year‑old patient with aggressive Grade 3 non‑germinal center B‑cell diffuse large B‑cell lymphoma (DLBCL) — who had failed three prior state‑of‑the‑art treatment regimens, including CAR‑T cell therapy and a CD3xCD20 bispecific antibody — achieved a confirmed complete metabolic response after just two 28‑day cycles of LP‑284. To date, LP‑284 has been well tolerated, with primarily Grade 1–2 adverse events reported. Market Opportunity and Unmet Need MCL and DHL are aggressive B‑cell lymphomas characterized by high relapse rates and poor prognoses. Nearly all MCL patients acquire resistance to and relapse from standard‑of‑care therapies, and patients with double‑hit lymphoma face particularly poor outcomes following relapse. Lantern estimates that LP‑284 targets a global market estimated at $4 billion annually for blood cancers, driven by the rising incidence of non‑Hodgkin's lymphoma globally, and has potential to address an estimated market that could improve outcomes for 40,000 to 80,000 blood cancer patients annually. About LP‑284 LP‑284 is an investigational next‑generation acylfulvene designed to exploit synthetic lethal interactions in cancer cells with DNA damage repair deficiencies. Developed through Lantern's RADR® AI platform, LP‑284 induces DNA lesions primarily repaired by transcription‑coupled nucleotide excision repair (TC‑NER), creating a distinct anti‑tumor profile. The compound's efficacy remains unaffected by TP53 mutation or lymphoma surface antigen expression, and preclinical studies demonstrate synergistic activity with rituximab and the ability to overcome ibrutinib resistance. LP‑284 is currently in Phase 1 evaluation (NCT06132503) and has received multiple FDA Orphan Drug Designations, including for mantle cell lymphoma, high‑grade B‑cell lymphomas, and soft tissue sarcomas. About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is an AI‑driven precision oncology company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary RADR® platform leverages machine learning and large‑scale genomic and clinical data — more than 200 billion oncology‑focused data points and a library of 200+ advanced machine learning algorithms — to identify biomarker signatures and guide the development of targeted therapies for patients with significant unmet need. Lantern's clinical‑stage pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with Lantern’s central-nervous-system focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open Medicine AI. For more information, visit . Forward‑Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; our patents and intellectual property profile; expectations and estimates regarding patent terms and coverage relating to LP-284; our clinical development plans, expectations and estimates regarding clinical trial timing and patient enrollment; estimates regarding patient populations, potential markets and potential market sizes; and our plans to discover and develop drug candidates and to maximize their commercial potential. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “model,” “objective,” “aim,” “upcoming,” “should,” “will,” “would,” or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (ii) the risk that a patent may not issue from an allowed application on the expected timeline or with the expected term, (iii) the risk that actual patent terms and coverage may differ from expectations, (iv) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (v) the risk that our research and the research of our collaborators may not be successful, (vi) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (vii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (viii) the risk that no drug product based on our proprietary AI platforms has received FDA marketing approval or otherwise been incorporated into a commercial product, and (ix) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 30, 2026. You may access our Annual Report on Form 10-K for the year ended December 31, 2025 under the investor SEC filings tab of our website at or on the SEC’s website at . Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations. Contacts Investor & Media Relations Email: IR@lanternpharma.com Phone: (972) 277‑1136